Inhibitor development in nonsevere hemophilia: data from the European Haemophilia Safety Surveillance (EUHASS) registry.

Res Pract Thromb Haemost · 2025 · PMC12178916 · PMID 40547964

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a nonsignificant trendno p-value reported

Of these, only Emoclot ( n = 1019) had more than 1000 treatment years, showing a nonsignificant trend toward reduced inhibitor development compared with Advate (IRR, 0.00; 95% CI, <0.01 to 1.09).

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.